Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2023)

Fast tracking informative clinical trials: lessons for mental health.

Gold SM. et al, (2023), Lancet Psychiatry

Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

LANDRAY M. et al, (2023), The Lancet

Facilitating participation in clinical trials during pregnancy.

Vousden N. et al, (2023), BMJ, 380

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.

Chapman D. et al, (2023), Kidney Int

A Pragmatic Randomized Feasibility Trial of Influenza Vaccines

Johansen ND. et al, (2023), NEJM Evidence, 2

Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation.

Bowman L. et al, (2022), Eur Heart J

Empagliflozin in Patients with Chronic Kidney Disease

HERRINGTON W. et al, (2022), New England Journal of Medicine

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials

HERRINGTON W. et al, (2022), The Lancet

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845

Determining the Relationship between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights from Genetic Epidemiology

HERRINGTON W. et al, (2022), Hypertension

Data provenance and integrity of health-care systems data for clinical trials.

Murray ML. et al, (2022), Lancet Digit Health, 4, e567 - e568

Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.

Peto L. et al, (2022), Adv Biol Regul

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

LANDRAY M. et al, (2022), The Lancet

Allocated but not treated: the silent 16%

Horby P. et al, (2022), LANCET, 399, 1776 - 1776

Allocated but not treated: the silent 16% - Authors' reply.

Horby P. et al, (2022), Lancet, 399, 1775 - 1776

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting: Rationale and Design of the DANFLU-1 Trial

LANDRAY M., (2022), Pilot and Feasibility Studies

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

RECOVERY Collaborative Group None. et al, (2022)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

HERRINGTON W., (2022), Nephrology, Dialysis and Transplantation

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?